Last week, I hosted an hourlong webinar on future directions for cancer immunotherapy. I focused my talk on three promising avenues of research: checkpoint inhibitors that target the protein called TIGIT; cell therapies utilizing NK, or natural killer, cells; and messenger RNA-based cancer vaccines.
The goal with all of these approaches is to increase the number of patients with cancer who can benefit from immunotherapy.
About the Author Reprints
Hi Adam,
I’m a rising oncology fellow at Northwestern Lurie Cancer Center in Chicago. I watched your immuno-oncology webinar recently and just wanted to say I thought it was outstanding. Really well done and look forward to seeing how some future milestones play out. Great presentation!